SCHEMBL7783153

SCHEMBL7783153

Cc1cc(C)cc(-n2c3ccccc3c3c(NCCNC4CCCCC4)cc(C)nc32)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
CYP2D6 P10635 2/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 4/20 0.36
CYP1A2 P05177 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA1 P30542 1/20 0.35
CXCR4 P61073 1/20 0.34
RAB9A P51151 1/20 0.34
MAPT P10636 1/20 0.34
CD38 P28907 1/20 0.34
RXFP1 Q9HBX9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7791844 0.99 NPY1R (0.43) NPY1RL3MBTL1KDM4EALDH1A1GAA
SCHEMBL7791825 0.86 NPY1R (0.43) NPY1RL3MBTL1KDM4EALDH1A1GAA
SCHEMBL7783178 0.85 NPY1R (0.44) NPY1RL3MBTL1KDM4EALDH1A1SMN1; SMN2
SCHEMBL7791105 0.76 CRHR1 (0.41) NPY1RKMT2ACD38
SCHEMBL7788898 0.76 CRHR1 (0.48) NPY1RL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL7788905 0.75 NPY1R (0.49) NPY1RALDH1A1GAALMNAKMT2A
SCHEMBL7788907 0.72 CRHR1 (0.42) NPY1RL3MBTL1KDM4EALDH1A1MAPT
SCHEMBL7676276 0.72 CRHR1 (0.49) ALDH1A1HPGDKMT2ARXFP1
SCHEMBL7675031 0.71 CRHR1 (0.45) KMT2ACD38
SCHEMBL7783147 0.71 CRHR1 (0.53) NPY1RKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NEUROGEN CORPORATION 2001-10-18 US claimed
US-6221875-B1 TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL NEUROGEN CORPORATION 2001-04-24 US claimed
WO-1999051598-A1 SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES: SELECTIVE NEUROPEPTIDE y RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1999-10-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NPY1R, NPY2R, NPY5R NPY1R 1/4885L3MBTL1 2026/4885KDM4E 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.